Drug updated on 7/25/2024
Dosage Form | Injection (intravenous: 500 mg (1,000 mg/m2 over 30 minutes)) |
Drug Class | Histone deacetylase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Belinostat (Beleodaq) is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
- The information was derived from two systematic reviews/meta-analyses.
- In terms of efficacy, belinostat has an overall response rate (ORR) of 10% in monotherapy for relapsed/refractory PTCL, which is lower compared to romidepsin and similar to chidamide.
- Combination therapies involving HDAC inhibitors like belinostat show superior efficacy compared to monotherapies, particularly in specific subtypes such as angioimmunoblastic T-cell lymphoma where higher ORRs are observed.
- Common adverse events associated with belinostat include thrombocytopenia and nausea; these safety profiles are consistent with other HDAC inhibitors used for treating PTCL and CTCL.
- Quality of life impacts were not specifically detailed for individual drugs, including belinostat, within the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Beleodaq (belinostat) prescribing information. | 2023 | Acrotech Biopharma LLC, East Windsor, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: A systematic review and meta-analysis on prospective clinical trials. | 2023 | Frontiers in Oncology |
The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: Results of a systematic review. | 2020 | Expert Review of Hematology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology. | 2022 | Journal of the National Comprehensive Cancer Network |